

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6188375

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
REBECCA COOK	04/14/2020
JOSEPH BLATTMAN	03/06/2020
TSAFRIR MOR	03/25/2020
RECEIVING PARTY DATA	
Name:	DIGNITY HEALTH
Street Address:	3033 N. THIRD AVE
City:	PHOENIX
State/Country:	ARIZONA
Postal Code:	85013
Name:	ARIZONA STATE UNIVERSITY
Street Address:	2020 N. CENTRAL AVE
City:	PHOENIX
State/Country:	ARIZONA
Postal Code:	85004
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15999241
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	ssenn@acceleratoraix.net
Correspondent Name:	ACCELERATOR AIX
Address Line 1:	124 E. OLIVE AVE
Address Line 4:	BURBANK, CALIFORNIA 91502
ATTORNEY DOCKET NUMBER:	DH-007US00
NAME OF SUBMITTER:	SEAN SENN
SIGNATURE:	/sean senn/
DATE SIGNED:	07/07/2020

Total Attachments: 3

source=Assignment for DH-007US00_cook_signed_____.tif

source=Assignment - Mor.tif

source=Assignment - Blattman.tif

ASSIGNMENT

WHEREAS, I, **Rebecca Cook** (hereinafter referred to as ASSIGNOR), am the inventor of an invention entitled "**ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER**", as described and claimed in U.S. National Application Serial No. 15/999,241 filed **August 17, 2018** and;

WHEREAS, **DIGNITY HEALTH** (hereinafter referred to as ASSIGNEE), having a principal place of business at 3033 North Third Avenue, Phoenix, Arizona, U.S.A., is desirous of acquiring the entire right, title and interest in and to the invention and in and to any patent that may be granted therefor in the United States and in any and all foreign countries.

THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE, the entire right, title and interest in and to said invention, said application and any and all patents which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States applications to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all patents on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the Commissioner for Patents and Trademarks to issue all patents on said invention to ASSIGNEE.

ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign patents on said invention, for litigation regarding said patents, or for the purpose of protecting title to said invention or patents therefor.

April 14, 2020
Date

By ASSIGNOR: 
Rebecca Cook

CONFIRMATORY ASSIGNMENT

SKYSONG ID: M17-125L-US1-a

WHEREAS, the undersigned inventors:

1. Tsafrir Mor 325 E. La Diosa Dr. Tempe, AZ 85282	2. Joseph Blattman 8695 E. Charter Oak Dr. Scottsdale, AZ 85260	3.	4.
5.	6.	7.	8.

(collectively, the “**Assignors**”) have invented certain new, useful, nonobvious, and otherwise patentable subject matter concerning

ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER

(the “**Inventions**”) for which the following United States patent application is filed herewith or was filed in the United States Patent and Trademark Office: serial number 15/999,241 filed on August 17, 2018 (the “**Assigned IP**”). The term “Assigned IP” further includes (1) all patent applications that claim priority to or from the patent application referenced or identified in the preceding sentence, whether a provisional application, a utility application, a design application, or other application, as well as any patent application that has been filed or will be filed and otherwise discloses one or more of the Inventions, (2) all other right, title, and interest in and to the Inventions, including but not limited to all other patent rights, copyrights, trade secrets or know-how, priority rights, rights to sue for past, present, and future damages, and all other rights in and to the Inventions, and (3) all patents, inventor's certificates, and other forms of protection granted thereon in the United States, in foreign countries or regions, or under any international convention, agreement, protocol, or treaty, including those arising under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or otherwise.

WHEREAS, Arizona State University is the Assignors’ employer and, in accordance with the Assignors’ employment agreements, the Arizona Board of Regents Intellectual Property Policy (ABOR 6-908 as of the date of this assignment), and/or other employment obligations, the Arizona Board of Regents on behalf of Arizona State University (the “**Assignee**”) already owns all right, title, and interest in and to the Inventions and the Assigned IP, including but not limited to all priority rights in, and all rights and entitlements to claim priority to and from, the Assigned IP.

WHEREAS, the Assignors are researchers employed by the Assignee who, in accordance with their employment agreements, Arizona Board of Regents Intellectual Property Policy, and/or other employment obligations: (1) have had an obligation to assign, and have in fact previously assigned to the Assignee, all right, title, and interest in the Inventions and the Assigned IP, including but not limited to all priority rights in, and all rights and entitlements to claim priority to and from, the Assigned IP, and (2) have an obligation to execute this confirmatory assignment for recordation purposes.

NOW, THEREFORE, in consideration of good and valuable consideration, including but not limited to Assignors’ eligibility to personally benefit from the Assignee’s Intellectual Property Management Implementation Policy (RSP 604 as of the date of this assignment):

- The Assignors do hereby sell, assign, transfer, and convey unto the Assignee the entire right, title, and interest (a) in and to the Inventions; (b) in and to the Assigned IP, including all priority rights in, and all rights and entitlements to claim priority to and from, any of the Assigned IP; (c) in and to each and every patent application that is a substitution, a continuation, a continuation-in-part, or a divisional, of any of the Assigned IP; (d) in and to each and every reissue, reexamination, renewal, or extension of any kind of any of the foregoing; (e) in and to each and every patent application of any kind filed outside the United States and corresponding to any of the foregoing, including but not limited to international (e.g., Patent Cooperation Treaty) applications; (f) in and to each and every patent or other form of protection, whether within or outside the United States, issuing or reissuing from any of the foregoing; and (g) in and to all claims for past, present, and future infringement of any of the Assigned IP, including all rights to sue for and to recover for the Assignee’s own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from any infringements of the Assigned IP.
- The Assignors will, at the Assignee’s request and expense, execute all rightful oaths, assignments, powers of attorney, declarations, or other papers, or provide written or oral testimony, that Assignee deems necessary to carry out, in good faith, the intent and purpose of this assignment or to otherwise assist Assignee in establishing its ownership rights.
- The Assignors hereby request that any patents or other forms of protection issuing in the United States, foreign countries or regions, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee or its successors, assigns, or legal representatives for the sole use of the Assignee and its successors, assigns, or legal representatives.
- The terms and conditions of this assignment shall be binding upon the Assignors and their respective successors, assigns, and legal representatives.
- This instrument will be interpreted and construed in accordance with the laws of the State of Arizona without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in physical or electronically transmitted individual counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, the Assignors have executed and delivered this instrument to the Assignee as of the dates written below:

1. **Tsafrir Mor**

Signature:
Date:




March 25, 2020

2. **Joseph Blattman**

Signature:
Date:

PATENT

REEL: 053140 FRAME: 0254

CONFIRMATORY ASSIGNMENT			SKYSONG ID: M17-125L-US1-a		
WHEREAS, the undersigned inventors:					
1. Tsafrir Mor 325 E. La Diosa Dr. Tempe, AZ 85282	2. Joseph Blattman 8695 E. Charter Oak Dr. Scottsdale, AZ 85260	3.	4.		
5.	6.	7.	8.		
<p>(collectively, the "Assignors") have invented certain new, useful, nonobvious, and otherwise patentable subject matter concerning</p> <p style="text-align: center;">ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER</p> <p>(the "Inventions") for which the following United States patent application is filed herewith or was filed in the United States Patent and Trademark Office: serial number <u>15/999,241</u> filed on <u>August 17, 2018</u> (the "Assigned IP"). The term "Assigned IP" further includes (1) all patent applications that claim priority to or from the patent application referenced or identified in the preceding sentence, whether a provisional application, a utility application, a design application, or other application, as well as any patent application that has been filed or will be filed and otherwise discloses one or more of the Inventions, (2) all other right, title, and interest in and to the Inventions, including but not limited to all other patent rights, copyrights, trade secrets or know-how, priority rights, rights to sue for past, present, and future damages, and all other rights in and to the Inventions, and (3) all patents, inventor's certificates, and other forms of protection granted thereon in the United States, in foreign countries or regions, or under any international convention, agreement, protocol, or treaty, including those arising under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or otherwise.</p> <p>WHEREAS, Arizona State University is the Assignors' employer and, in accordance with the Assignors' employment agreements, the Arizona Board of Regents Intellectual Property Policy (ABOR 6-908 as of the date of this assignment), and/or other employment obligations, the Arizona Board of Regents on behalf of Arizona State University (the "Assignee") already owns all right, title, and interest in and to the Inventions and the Assigned IP, including but not limited to all priority rights in, and all rights and entitlements to claim priority to and from, the Assigned IP.</p> <p>WHEREAS, the Assignors are researchers employed by the Assignee who, in accordance with their employment agreements, Arizona Board of Regents Intellectual Property Policy, and/or other employment obligations: (1) have had an obligation to assign, and have in fact previously assigned to the Assignee, all right, title, and interest in the Inventions and the Assigned IP, including but not limited to all priority rights in, and all rights and entitlements to claim priority to and from, the Assigned IP, and (2) have an obligation to execute this confirmatory assignment for recordation purposes.</p> <p>NOW, THEREFORE, in consideration of good and valuable consideration, including but not limited to Assignors' eligibility to personally benefit from the Assignee's Intellectual Property Management Implementation Policy (RSP 604 as of the date of this assignment):</p> <ol style="list-style-type: none"> 1. The Assignors do hereby sell, assign, transfer, and convey unto the Assignee the entire right, title, and interest (a) in and to the Inventions; (b) in and to the Assigned IP, including all priority rights in, and all rights and entitlements to claim priority to and from, any of the Assigned IP; (c) in and to each and every patent application that is a substitution, a continuation, a continuation-in-part, or a divisional, of any of the Assigned IP; (d) in and to each and every reissue, reexamination, renewal, or extension of any kind of any of the foregoing; (e) in and to each and every patent application of any kind filed outside the United States and corresponding to any of the foregoing, including but not limited to international (e.g., Patent Cooperation Treaty) applications; (f) in and to each and every patent or other form of protection, whether within or outside the United States, issuing or reissuing from any of the foregoing; and (g) in and to all claims for past, present, and future infringement of any of the Assigned IP, including all rights to sue for and to recover for the Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from any infringements of the Assigned IP. 2. The Assignors will, at the Assignee's request and expense, execute all rightful oaths, assignments, powers of attorney, declarations, or other papers, or provide written or oral testimony, that Assignee deems necessary to carry out, in good faith, the intent and purpose of this assignment or to otherwise assist Assignee in establishing its ownership rights. 3. The Assignors hereby request that any patents or other forms of protection issuing in the United States, foreign countries or regions, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee or its successors, assigns, or legal representatives for the sole use of the Assignee and its successors, assigns, or legal representatives. 4. The terms and conditions of this assignment shall be binding upon the Assignors and their respective successors, assigns, and legal representatives. 5. This instrument will be interpreted and construed in accordance with the laws of the State of Arizona without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in physical or electronically transmitted individual counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement. <p>IN WITNESS WHEREOF, the Assignors have executed and delivered this instrument to the Assignee as of the dates written below:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 10px;"> <p>1. Tsafrir Mor</p> <p>Signature: _____</p> <p>Date: _____</p> </td> <td style="width: 50%; vertical-align: top; padding: 10px;"> <p>2. Joseph Blattman</p> <p>Signature: </p> <p>Date: _____</p> </td> </tr> </table>				<p>1. Tsafrir Mor</p> <p>Signature: _____</p> <p>Date: _____</p>	<p>2. Joseph Blattman</p> <p>Signature: </p> <p>Date: _____</p>
<p>1. Tsafrir Mor</p> <p>Signature: _____</p> <p>Date: _____</p>	<p>2. Joseph Blattman</p> <p>Signature: </p> <p>Date: _____</p>				

PATENT

RECORDED: 07/07/2020

REEL: 053140 FRAME: 0255